Status:
UNKNOWN
Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis
Lead Sponsor:
Tehran University of Medical Sciences
Collaborating Sponsors:
Boston University
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Adult ALL
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
Investigating the effects of hydroxyvitamin D3 on clinical, radiologic and immunomodulatory markers in MS patients: A randomized, clinical trial- a pilot study
Detailed Description
Vitamin D deficiency/insufficiency is a risk factor for developing MS and is linked to increased disease activity in those with established disease. Several clinical trials have already been conducted...
Eligibility Criteria
Inclusion
- MS type: relapsing-remitting MS (RRMS)
- older than 18 year-old
- Vitamin D deficiency/insufficiency (25(OH)D\<30 ng/ml
Exclusion
- medications or disorders that would affect vitamin D metabolism
- history of other chronic disorders
- history of conditions that could lead to high serum calcium levels
- pulse therapy in the last 3 months
- history of attack in the last 3 months
- using corticosteroid in the last 3 months
- be pregnant
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT05340985
Start Date
July 1 2022
End Date
December 1 2023
Last Update
April 22 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.